Lantern Pharma Inc. financial data

Symbol
LTRN on Nasdaq
Industry
Pharmaceutical Preparations
Location
1920 Mckinney Avenue, 7 Th Floor, Dallas, Texas
State of incorporation
Texas
Fiscal year end
December 31
Former names
Lantern Pharma (to 1/14/2019)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.23K % -36.5%
Debt-to-equity 8.97 % +60.8%
Return On Equity -46.4 % -75.6%
Return On Assets -42.6 % -70.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 10.8M shares -0.96%
Common Stock, Shares, Outstanding 10.8M shares -1.01%
Entity Public Float 52.6M USD +3.07%
Common Stock, Value, Issued 1.08K USD -1.01%
Weighted Average Number of Shares Outstanding, Basic 10.8M shares -0.91%
Weighted Average Number of Shares Outstanding, Diluted 10.8M shares -0.91%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 13.9M USD +53.6%
General and Administrative Expense 5.62M USD -12%
Operating Income (Loss) -19.5M USD -26.5%
Net Income (Loss) Attributable to Parent -17.7M USD -24.5%
Earnings Per Share, Basic -1.64 USD/shares -24.2%
Earnings Per Share, Diluted -1.64 USD/shares -4.55%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 13M USD -54.3%
Marketable Securities, Current 20.3M USD +3.89%
Assets, Current 35.3M USD -30.9%
Property, Plant and Equipment, Net 50.3K USD +0.68%
Operating Lease, Right-of-Use Asset 213K USD -30.9%
Other Assets, Noncurrent 32K USD +23.8%
Assets 35.6M USD -30.8%
Liabilities, Current 4.6M USD +52.5%
Operating Lease, Liability, Noncurrent 54.7K USD -63.7%
Liabilities 4.66M USD +47%
Accumulated Other Comprehensive Income (Loss), Net of Tax -6.59K USD +97.5%
Retained Earnings (Accumulated Deficit) -65.6M USD -37.1%
Stockholders' Equity Attributable to Parent 30.9M USD -35.9%
Liabilities and Equity 35.6M USD -30.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.07M USD +18.3%
Net Cash Provided by (Used in) Financing Activities 54.7K USD
Net Cash Provided by (Used in) Investing Activities -556K USD +42.1%
Common Stock, Shares Authorized 25M shares 0%
Common Stock, Shares, Issued 10.8M shares -1.01%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.58M USD +24.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 47.2M USD -42%
Deferred Tax Assets, Valuation Allowance 12.5M USD +36.6%
Deferred Tax Assets, Gross 12.5M USD +36.6%
Operating Lease, Liability 219K USD -30.3%
Payments to Acquire Property, Plant, and Equipment 2.22K USD -75%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -17.5M USD -23.4%
Lessee, Operating Lease, Liability, to be Paid 233K USD -30.8%
Operating Lease, Liability, Current 164K USD +0.53%
Lessee, Operating Lease, Liability, to be Paid, Year Two 62.4K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 140K USD -24%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure +27.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 14.2K USD -37.7%
Deferred Tax Assets, Operating Loss Carryforwards 7.38M USD +14%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Operating Lease, Payments 45K USD +7.14%
Additional Paid in Capital 96.6M USD +0.17%
Preferred Stock, Shares Outstanding 0 shares
Operating Leases, Future Minimum Payments, Due in Two Years 120K USD
Depreciation, Depletion and Amortization 4.06K USD +18.8%
Deferred Tax Assets, Net of Valuation Allowance 3.85K USD +5.16%
Operating Leases, Future Minimum Payments, Due in Three Years 53.4K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%